1-[4-([1,3]Thiazolo[4,5-b]pyridin-2-yloxy)benzyl]piperidine-4-carboxamide | 1190925-20-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[4-([1,3]Thiazolo[4,5-b]pyridin-2-yloxy)benzyl]piperidine-4-carboxamide
• 英文别名: 1-[[4-([1,3]Thiazolo[4,5-b]pyridin-2-yloxy)phenyl]methyl]piperidine-4-carboxamide
• CAS: 1190925-20-2
• 化学式: C₁₉H₂₀N₄O₂S
• 分子量: 368.459
• InChiKey: OXQZNSJFIPMIBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  哌啶-4-甲酰胺 、 4-([1,3]thiazolo[4,5-b]pyridin-2-yloxy)benzaldehyde 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 以53%的产率得到1-[4-([1,3]Thiazolo[4,5-b]pyridin-2-yloxy)benzyl]piperidine-4-carboxamide
  参考文献：
  名称：

  Azabenzthiazole inhibitors of leukotriene A4 hydrolase

  摘要：

  Previously, benzthiazole containing LTA4H inhibitors were discovered that were potent (1-3), but were associated with the potential for a hERG liability. Utilizing medicinal chemistry first principles (e. g., introducing rigidity, lowering cLogD) a new benzthiazole series was designed, congeners of 1-3, which led to compounds 7a, 7c, 12a-d which exhibited LTA4H IC50 = 3-6 nM and hERG Dofetilide Binding IC50 = 8.9-> >10 mu M. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.036

文献信息

• Treatment of Pulmonary Hypertension with Leukotriene Inhibitors
  申请人：THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：US20130251787A1

  公开（公告）日：2013-09-26

  Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene A 4 hydrolase (LTA 4 H) inhibitors, leukotriene B 4 receptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxgygenase activating protein (FLAP) inhibitors.

  肺动脉高压（PAH）可以在易患该病的人群中预防，并且可以通过给予有效剂量的白细胞三烯抑制剂来治疗PAH患者。合适的抑制剂包括白细胞三烯A4水解酶（LTA4H）抑制剂、白细胞三烯B4受体（BLT1/BLT2）拮抗剂、5-脂氧合酶（5-LO）抑制剂和5-脂氧合酶激活蛋白（FLAP）抑制剂。
• Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
  申请人：Bacani Genesis M.

  公开号：US20090258854A1

  公开（公告）日：2009-10-15

  Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.

  描述了噻唑吡啶-2-氧基苯基和噻唑吡嗪-2-氧基苯基胺化合物，这些化合物可作为LTA4水解酶（LTA4H）调节剂。这些化合物可以用于制备药物组合物，用于调节LTA4H并治疗由LTA4水解酶活性介导的疾病状态、疾病和症状。
• Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
  申请人：Bacani Genesis M.

  公开号：US20110159563A1

  公开（公告）日：2011-06-30

  Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.

  本文介绍了一种Thiazolopyridin-2-yloxy-phenyl和thiazolopyrazin-2-yloxy-phenyl胺类化合物，这些化合物可用作LTA4水解酶（LTA4H）调节剂。这些化合物可以用于制备药物组合物和方法，用于调节LTA4H并治疗由LTA4水解酶活性介导的疾病状态、疾患和病情。
• Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
  申请人：Alkahest, Inc.

  公开号：US11344542B2

  公开（公告）日：2022-05-31

  Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

  本文描述了治疗和/或预防衰老相关疾病的方法和组合物。这些方法中使用的组合物包括白三烯 A4水解酶（"LTA4H"）的抑制剂或拮抗剂，具有治疗和/或预防神经认知障碍等衰老相关疾病的功效。
• THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2268646B1

  公开（公告）日：2013-10-02